Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motexafin gadolinium + docetaxel
- Development stage
- Unknown
- Lead developer
- Pharmacyclics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Motexafin gadolinium + docetaxel is an investigational **combination regimen** consisting of motexafin gadolinium, a redox-active porphyrin-like compound, and docetaxel, a microtubule inhibitor. Motexafin gadolinium accumulates selectively in cancer cells and disrupts redox balance, inducing oxidative stress and apoptosis by generating reactive oxygen species and interfering with cellular antioxidant systems. Docetaxel binds to tubulin and promotes the assembly of microtubules while inhibiting their disassembly, blocking cell division and leading to cell death. The combination has been evaluated in clinical trials, primarily for advanced cancer including non-small cell lung cancer (NSCLC), based on preclinical evidence for synergistic antitumor effects and enhanced chemotherapy efficacy[1][2][4][8]. The primary developer for motexafin gadolinium is Pharmacyclics.
- Brand names
- Xcytrin (motexafin gadolinium)Taxotere (docetaxel)
- Other names
- MGd + docetaxel
02
Targets
RRM2TXNRD1 (Thioredoxin reductase 1)PRDX5 (Peroxiredoxin-5)TUBB (Tubulin (alpha and beta subunits))TXNRD2 (Thioredoxin reductase 2)
Beyond the preview
Go deeper on motexafin gadolinium + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motexafin gadolinium + docetaxel.